210 related articles for article (PubMed ID: 32880385)
1. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.
Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J
Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
[No Abstract] [Full Text] [Related]
3. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
4. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.
Alves MR; Do Amaral NS; Marchi FA; Silva FIB; Da Costa AABA; Carvalho KC; Baiocchi G; Soares FA; De Brot L; Rocha RM
Oncol Rep; 2019 Apr; 41(4):2254-2264. PubMed ID: 30720106
[TBL] [Abstract][Full Text] [Related]
7. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
Sato M; Sato S; Shintani D; Hanaoka M; Ogasawara A; Miwa M; Yabuno A; Kurosaki A; Yoshida H; Fujiwara K; Hasegawa K
BMC Cancer; 2022 Jan; 22(1):59. PubMed ID: 35027024
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing acts as an independent prognosticator in ovarian carcinoma.
Ouyang Y; Xia K; Yang X; Zhang S; Wang L; Ren S; Zhou H; Liu Y; Tang F
Sci Rep; 2021 May; 11(1):10413. PubMed ID: 34001978
[TBL] [Abstract][Full Text] [Related]
10. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
[TBL] [Abstract][Full Text] [Related]
11. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.
Mhawech-Fauceglia P; Wang D; Samrao D; Godoy H; Ough F; Liu S; Pejovic T; Lele S
Gynecol Oncol; 2012 Oct; 127(1):198-201. PubMed ID: 22705448
[TBL] [Abstract][Full Text] [Related]
12. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC).
Yang X; Liu Q; Zou J; Li YK; Xie X
Cancer Manag Res; 2021; 13():5683-5698. PubMed ID: 34295189
[TBL] [Abstract][Full Text] [Related]
14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
15. A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma.
Shen Y; Huang Q; Zhang Y; Hsueh CY; Zhou L
Cancer Cell Int; 2022 Jul; 22(1):226. PubMed ID: 35804447
[TBL] [Abstract][Full Text] [Related]
16. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
17. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
18. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract][Full Text] [Related]
19.
Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
[No Abstract] [Full Text] [Related]
20. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
